Volume 1, Issue 5
Editorialp. 605
Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial
Author(s): Giuliano Tocci, Diana Chin, Massimo Volpe
Editorialp. 611
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Author(s): Ciro Gallo, Francesco Perrone
Editorialp. 615
Vitamin D as an adjuvant therapy for tuberculosis: pharmacogenomic implications
Author(s): Dilip Nazareth, Peter Davies
Clinical Trail Outcomesp. 623
Developing an international network for breast cancer research: the BIG experience
Author(s): Michael Gnant, Martine Piccart-Gebhart, Aron Goldhirsch, Jose Baselga, David Cameron, Angelo Di Leo, Mitchell Dowsett, Richard Gelber, Gunter von Minckwitz, Cecilia Waldvogel, Carolyn Straehle
Clinical Trail Outcomesp. 629
Ethical issues in adult oncology randomized clinical trials
Author(s): Erika P Hamilton, Jeffrey M Peppercorn
Review Articlep. 637
An approach to personalized medicine: the BATTLE trial
Author(s): Niels Reinmuth & Michael Thomas
Review Articlep. 651
Adjuvant trials for pancreatic cancer: where are we going and what is needed?
Author(s): Suzanne Russo, Roger Ove, Carlo Contreras, Muhammad Wasif Saif
Review Articlep. 669
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Author(s): Nicole G Chau, Bonnie S Glisson
Review Articlep. 1
Combination therapy for renal cell carcinoma: review of the clinical evidence
Author(s): David F McDermott, Keith T Flaherty
Review Articlep. 699
An approach to personalized medicine: the BATTLE trial
Author(s): Niels Reinmuth, Michael Thomas
Review Articlep. 707
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Author(s): Massimo Breccia, Giuliana Alimena
Review Articlep. 719
Selective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence
Author(s): Tobias Johannes de Villiers
Review Articlep. 725
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Author(s): Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
News and Viewsp. 23–27
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
Acknowledgementsp. 757
